Battle Intensifies As SBF Requests Adderall For Trial To Resume

Key Points:

• Sam Bankman-Fried’s lawyers express concern over his lack of access to prescribed medication, Adderall, potentially affecting his ability to testify in court.
• The defense team proposes administering a 12-hour extended-release dose of Adderall, but it is uncertain if the Bureau of Prisons will provide it in time for the trial to resume.

Sam Bankman-Fried’s lawyers express concern about him not receiving Adderall, potentially affecting his ability to testify. The lawyers and SBF requests Adderall ensure a fair trial process.

In a letter addressed to Judge Kaplan, they explained that despite not having access to Adderall during trial hours, Mr. Bankman-Fried has been trying his best to stay focused during the past two weeks of the trial.

However, as the defense case approaches and the decision of whether Mr. Bankman-Fried will testify becomes crucial, the defense team is increasingly worried that his inability to access Adderall has hindered his concentration, potentially preventing him from meaningfully participating in the presentation of the defense case.

SBF Requests Adderall For His Testimony

The defense has made efforts to address this issue with the Bureau of Prisons (BOP), but they have not received a response to their numerous emails and voice messages. They proposed administering a 12-hour extended-release 20mg dose of Adderall to Mr. Bankman-Fried in the morning before he is transported to the courthouse for trial.

While they hope that this modification will resolve the situation, it remains uncertain whether the BOP will be able to provide the extended-release dose in time for the trial to resume on Monday. Furthermore, even if the dose is provided, it is unknown whether it will effectively help Mr. Bankman-Fried.

Coincu will continue to update the situation related to Sam Bankman-Fried, you can find out more information through this article.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.